Apoptosis markers can serve as valuable indicators for therapeutic interventions and regulating them can help restore the balance between cell survival and death. Additionally, early and accurate detection of apoptosis can improve drug efficacy evaluations, contributing to advancements in treatments for apoptosis-related conditions.

Apoptosis pathways and key markers

Apoptosis is a highly regulated and complex process involving distinct pathways and protein markers that signal and execute programmed cell death, essential for cellular health and immune defense. Each pathway and set of markers contribute uniquely to controlling cell survival and death in response to both internal and external signals. We can identify apoptosis using assays based on the sample type (tissue samples or cell culture) and the number of cells.

The extrinsic pathway

The extrinsic pathway of apoptosis is an important energy-dependent process that initiates programmed cell death in response to signals from outside the cell, primarily through interactions with immune cells like natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). This pathway plays a vital role in immune defense by targeting and eliminating infected or transformed cells that may lead to diseases, including cancer. NK cells, part of the innate immune system, detect stress signals on aberrant (non-healthy) cells, while CTLs, part of the adaptive immune system, recognize specific antigens presented by infected or abnormal cells.

The process begins when death receptors on the cell surface bind with ligands, forming a death-inducing signaling complex (DISC) that activates caspase proteins. The death receptors (such as Fas (CD95), TRAIL receptors, and TNF receptors) are members of the tumor necrosis factor (TNF) gene superfamily and consist of cysteine-rich extracellular domains and conserved intracellular ‘death domains.’ The DISC contains the adaptor protein procaspase-8 and procaspase-10, facilitating a controlled cell death without triggering inflammation.

Receptor-interacting protein 1 (RIP1) plays an important role in switching between death and survival signaling. The extrinsic pathway is essential not only for pathogen clearance but also for maintaining immune tolerance and preventing autoimmune responses by eliminating self-reactive cells.

The intrinsic pathway

The intrinsic pathway of apoptosis, also known as the mitochondrial pathway, is triggered by internal cell stressors like DNA damage, oxidative stress, or lack of survival signals. This pathway is tightly regulated by the B-cell lymphoma-2 (Bcl-2) protein family, which includes both pro-apoptotic proteins (such as Bax and Bak) and anti-apoptotic proteins (like Bcl-2 and Bcl-XL) on the mitochondrial membrane.

When pro-apoptotic signals dominate, they cause the mitochondrial membrane to become permeable, releasing Cytochrome C into the cytoplasm. Cytochrome C then binds to apoptotic protease activating factor-1 (Apaf-1) and pro-caspase-9 to form the apoptosome, which activates caspase-9 and, subsequently, the effector or (executioner) caspases (caspase-3, -6, -7, and -14), leading to cellular breakdown and death.

This process is essential for removing damaged cells. It is a central focus in cancer therapies, as defects in the intrinsic pathway can contribute to treatment resistance, including resistance to chemotherapy. The pathway is highly regulated, with Smac/DIABLO also released from the mitochondria to the cytosol to inhibit IAPs (inhibitors of apoptosis proteins), further promoting apoptosis and ensuring the cell's self-destruction when needed.

Cytochrome c oxidase subunit 4 (COX-4) plays an indirect but key part in detecting the intrinsic pathway, as it has a role in mitochondrial function and signaling. COX-4 is required for ATP production in the mitochondrial electron transport chain. Changes in the levels of COX-4 or its function can potentially indicate mitochondrial integrity and stress, closely associated with the intrinsic pathway of apoptosis.

Common apoptosis markers

Apoptosis markers are proteins that play key roles in programmed cell death by cleaving specific cellular substrates. Caspases are markers classified, based on their N-terminal domains, into initiator (eg, caspases -2, -8, -9, and -10) and effector caspases (eg, caspase-3, -6, and -7), which activate and execute the cell death process respectively. Apoptotic signals activate initiator caspases, which, in turn, activate effector caspases to break down cellular components. The regulation and inhibition of caspases by IAPs are essential for controlling apoptosis in both normal and disease states.

• Poly (ADP-ribose) polymerase (PARP) plays an essential role in apoptosis. It is a nuclear enzyme that plays a role in DNA repair, DNA stability, and transcriptional regulation and is activated by binding to DNA ends or strand breaks. When PARP remains active, it accelerates cell death, as its continuous activity can deplete these important resources, pushing cells toward apoptosis. This process also triggers early DNA fragmentation and caspase-3 activation, showing that PARP plays a complex role in balancing energy preservation and cell death signaling. PARP is inactivated by caspase-3 to preserve cellular energy resources like NAD and ATP.

• The FAS/FASL and death receptors are involved in extrinsic apoptosis signaling and can serve as markers, especially in immune-mediated apoptosis.

• The Bcl-2 protein family plays a central role in regulating apoptosis, the programmed cell death process that is vital for maintaining cellular balance, immune response, and preventing disease progression. Members of this family are divided into three groups based on their functions:

  • Pro-survival proteins (eg, Bcl-2, Bcl-xL, myeloid cell leukemia-1 or Mcl1, Bcl-W, and BFL-1/A1)
  • Pro-apoptotic effectors (eg, Bax, Bak, Bok)
  • BH3-only proteins (eg, Bad, Bim, Puma, Bid, Bik, Bmf, Noxa, Puma), which act as apoptosis initiators.

The decision to initiate apoptosis hinges on interactions between these proteins, particularly at the mitochondrial membrane.

IAPs regulate cell survival by inhibiting caspases. Key IAPs like X-linked inhibitors of apoptosis (XIAP) directly bind and inhibit caspases-3 and -9. SMAC/DIABLO and the high-temperature requirement A2 (HtrA2)/Omi counteract IAPs, promoting apoptosis.

Types of apoptosis antibodies

Antibodies are important for studying apoptosis, allowing researchers to target specific proteins involved in initiating, executing, and regulating cell death pathways.

Using antibodies in apoptosis research involves challenges in distinguishing apoptosis from necrosis, necroptosis, and ferroptosis due to their distinct markers and mechanisms. These are distinct types of cell death, each with unique triggers and markers.

• Apoptosis is a programmed cell death that helps maintain tissue homeostasis, marked by caspase activation, membrane blebbing, and DNA fragmentation, detectable through Annexin V staining.
• Necrosis, typically unregulated, is induced by extreme stress, leading to rapid cell swelling, plasma membrane rupture, and release of intracellular contents, which can be observed with propidium iodide (PI) uptake. Unlike apoptosis, necrosis is inflammatory due to the release of cellular content.
• Ferroptosis is an iron-dependent, lipid peroxidation-driven cell death prevented by ferroptosis inhibitors like ferrostatin-1, which differentiates it from other forms.
• Necroptosis, a regulated form of necrosis, involves RIPK1 and RIPK3, while necrostatin-1 can inhibit it.

Using specific antibodies for markers, such as caspase-3 for apoptosis and RIPK3 for necroptosis, helps in correctly identifying cell death types. Differentiating these pathways is important, as misidentification could lead to flawed conclusions about cell responses in disease and treatment research.

Antibodies targeting initiator caspases

Initiator caspases are proteins that trigger the start of apoptosis by activating downstream pathways leading to cell death. Antibodies targeting caspase-8, caspase-9, and caspase-10 can help study and identify these initial apoptotic signals.

Antibodies targeting effector caspases

Effector caspases, such as caspase-3 and caspase-7, execute apoptosis by degrading vital cellular proteins. These antibodies are essential tools for detecting apoptosis progression and analyzing cellular death mechanisms.

Antibodies for cleaved substrates

Cleaved substrate antibodies detect fragments produced by caspase activity during apoptosis, providing insight into the extent of cellular damage. They are widely used to track apoptotic events in real-time in various assays. Caspase-3 antibodies detect both uncleaved and cleaved versions of the enzyme and are strong indicators of cell death. Likewise, caspase-3 activation causes the PARP protein (nearly 116 kDa; pro form, full length) to cleave into 89 kDa and 26 kDa fragments (cleaved forms).

Antibodies to determine the balance between pro- and anti-apoptosis proteins

Bcl-2 family proteins regulate cell survival and death by controlling mitochondrial membrane permeability. Antibodies for Bcl-2 and related proteins, such as Bcl-xl, Bax, Bak, Bad, and Bid, help study the balance of pro-survival and pro-apoptotic signals within cells.

Key techniques for detecting apoptosis using antibodies

Researchers use various techniques to identify and measure specific markers associated with cell death processes to study apoptosis. These methods, such as western blotting, flow cytometry, immunohistochemistry, immunocytochemistry, and ELISA, offer unique insights into the stages and mechanisms of apoptosis, aiding in both research and clinical diagnostics.

Western blot for apoptosis detection

Western blotting allows researchers to detect and quantify specific proteins involved in apoptosis by using antibodies that bind to target proteins in cell or tissue lysates. This technique provides insights into the expression levels and post-translational modifications of proteins at various stages of apoptosis, revealing details about cellular signaling events.

Western blotting is a standard and reliable method for studying apoptosis. It allows for a repeatable method with the use of well-characterized recombinant monoclonal antibodies and quantification-based analysis. For example, researchers can detect apoptosis based on the levels of Cytochrome-C and COX 4 in the mitochondrial fractions.

It can be used to study apoptosis by analyzing apoptotic proteins, unfolded protein response pathways of the mitochondria and endoplasmic reticulum and death receptor stimulation. During western blotting, proteins are first separated by size through gel electrophoresis, which allows researchers to distinguish between target proteins and other cellular components. The separated proteins are then transferred to a membrane, creating a stable platform for antibody binding and detection.

Selecting the appropriate antibody, preferably a recombinant monoclonal antibody, is essential to target specific apoptosis markers accurately. Primary antibodies bind to apoptosis-related proteins, and secondary antibodies help visualize these interactions, allowing for the detection of apoptotic phases and pathways.

Immunohistochemistry and immunocytochemistry

Immunohistochemistry (IHC) with apoptosis-specific antibodies is a powerful tool for visualizing cell death in tissue samples. By targeting proteins like cleaved caspase-3, cleaved cytokeratin-18, and phosphorylated histone H2AX, IHC can be used to identify apoptotic cells within tissue sections. This staining approach differentiates apoptotic cells from healthy or necrotic ones, providing clear insights into cell death stages and patterns. Widely applied in cancer research, this technique helps researchers understand cellular responses to treatments and stress in various disease contexts.

Immunocytochemistry with apoptosis antibodies allows researchers to visualize programmed cell death in tissue and cell samples. By targeting caspases, the key proteins in the apoptosis cascade, this technique highlights apoptotic markers such as caspase-3, -6, -8, and -9 within cells. These markers can reveal cytoplasmic and nuclear localization of apoptosis-associated proteins, providing insight into cellular processes and disease states, such as high-grade tumors. Such visualization aids in identifying cells undergoing programmed cell death and can support prognostic assessments or guide therapeutic strategies for cancers.

ELISA for apoptosis detection

ELISA can be used to detect apoptosis based on the release of nucleosomes into the cytoplasm, a hallmark of apoptotic cell death marked by DNA fragmentation. This process employs a “sandwich” technique, where first, a monoclonal antibody captures nucleosomes on the ELISA plate by binding to histone proteins exposed during chromatin breakdown. A second, biotinylated detection monoclonal antibody then binds to these captured nucleosomes, forming a detectable complex.

In practice, cytoplasmic lysates from apoptotic cells are added to plates pre-coated with the capture antibody, which binds nucleosomes present in the sample. After washing away unbound substances, the detection antibody and a conjugated enzyme (eg, alkaline phosphatase linked to streptavidin) are added. This enzyme reacts with a substrate to produce a color change, which can be quantified by measuring optical density. ELISA’s high sensitivity allows it to detect apoptosis at low cell counts and provides quantitative data on apoptotic activity, making it particularly useful in cancer research and drug testing.

Selecting the right apoptosis antibody for your research

Selecting the appropriate antibody for apoptosis research requires careful consideration of factors such as specificity, sensitivity, species reactivity, and antibody type to achieve reliable and accurate experimental results.

Criteria for antibody selection

Selecting the right apoptosis antibody involves ensuring high specificity and sensitivity to target apoptotic markers accurately in experimental models. Specificity ensures the antibody binds precisely to the target protein, while sensitivity determines its effectiveness in detecting even low levels of apoptotic signals.

When selecting an antibody, checking species reactivity is important to ensure compatibility with your experimental model. Most antibodies are produced based on human protein sequences, but cross-reactivity with other species should be confirmed on the antibody datasheet or through sequence alignment.

The advantage of recombinant monoclonal antibodies for apoptosis detection

Recombinant monoclonal antibodies provide high specificity by binding to a single epitope, lowering non-specific binding.

Abcam provides several recombinant monoclonal antibody kits to study apoptosis, such as the apoptosis western blot cocktail (pro/p17-caspase-3, cleaved PARP1, muscle actin) and the apoptosis antibody sampler panel (Bad, Bax, Bcl-2, Bcl-XL, and MCL1).

Importance of validation

Validating apoptosis antibodies ensures that they provide specific, selective, and reproducible results across different applications. The validation process involves confirming that the antibody targets the protein of interest without cross-reacting with unrelated proteins, which is important for accurate apoptosis detection. Techniques like western blotting, immunoprecipitation, and the use of knockout models help assess antibody specificity and effectiveness. This rigorous approach minimizes false positives and ensures reliable data in apoptosis research.

Applications of apoptosis antibodies in research and diagnostics

Apoptosis is a fundamental biological process that plays an important role in disease progression, diagnosis, and therapeutic intervention across various fields of medical research.

Apoptosis in cancer research

Detecting apoptosis in tumors is vital for understanding therapeutic efficacy in drug discovery, as it provides insight into a treatment's ability to selectively induce cell death in cancer cells.

Apoptosis detection relies on markers such as caspase activation, phosphatidylserine exposure, and DNA fragmentation, which indicate programmed cell death. By targeting apoptotic pathways, drug discovery can focus on agents that promote tumor cell apoptosis while minimizing damage to healthy cells, making it a valuable approach in cancer treatment research.

Apoptosis in neurodegenerative disease studies

In diseases like Alzheimer’s and Parkinson’s, apoptosis plays an important role, leading to progressive neuronal death and worsening cognitive and motor functions. Targeting apoptosis pathways is a therapeutic focus in trying to prevent or slow neurodegeneration. Screening these pathways for therapeutic targets aims to inhibit or modify cell death processes with approaches that include antioxidant therapies and caspase inhibitors to reduce cellular damage and improve neuron survival.

Diagnostic tools in clinical settings

Apoptosis antibodies may serve as valuable diagnostic markers in conditions like cancer by identifying specific proteins involved in the cell death process, such as caspases and cytokeratins. In cancer, monitoring apoptotic markers can provide insights into tumor behavior and therapeutic response, as these antibodies help detect apoptotic activity in blood samples or tissue biopsies. The level of Cytochrome C was found to be a sensitive marker of apoptosis reflecting cell death induced due to therapy¹.

Analysis of sera samples of patients and survival data showed that patients with normal Cytochrome C levels three years ago had a two-fold probability of being alive. Apoptosis is the primary cause of the release of ctDNA: single- or double-stranded DNA molecules from tumor cells. Interestingly, the level of cfDNA or the total cell-free DNA in the blood in lung cancer patients compared to normal people². Additionally, mutations in the ctDNA are correlated with those seen in biopsies, highlighting the potential of apoptosis screening. The Bcl-2 family has been implicated in blood cancers such as lymphoma.

Apoptosis antibodies may also serve as diagnostic markers in autoimmune diseases by identifying specific apoptotic processes, particularly in conditions like psoriasis and autoimmune thyroid diseases. These markers, often related to proteins from the Bcl-2 family and caspases, may be used to monitor the apoptosis pathways linked to disease progression and immune response dysregulation. By detecting pro- and anti-apoptotic markers, clinicians can gain insights into disease severity and response to treatment, aiding in the management of autoimmune disorders.

The expression of Bcl-2 was higher in patients with the autoimmune disease systemic lupus erythematosus compared to controls. The Bcl-2 family has also been related to autoimmune blood disorders, such as idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and autoimmune neutropenia^3,4.

Developments in apoptosis research

Advancements in apoptosis research are unveiling new technologies, pathways, and therapeutic strategies that are reshaping our approach to disease treatment, particularly in cancer therapy.

Emerging technologies in apoptosis detection

Emerging technologies in apoptosis detection are advancing beyond traditional methods like electron microscopy and flow cytometry to include innovations such as microfluidic devices, single-molecule spectroscopy, biosensors, and electrochemical methods. Additionally, live-cell imaging, molecular imaging probes, and AI-integrated data analysis are enhancing the precision and efficiency of apoptosis research⁵.

In one study, apoptosis was detected using a novel hybrid 3D printed and paper-based microfluidic platform⁶. For positron emission tomography-based imaging of apoptosis, a novel tracer called [18F] MICA-316 was developed that could selectively bind to tumor cells to allow for improved apoptosis detection⁷.

Artificial intelligence and phase contrast microscopy could identify apoptosis and classify the microscopic images as caspase-negative/no DNA fragmentation, caspase-positive/no DNA fragmentation, and caspase-positive/DNA fragmentation. A deep learning-based apoptosis detection system is being developed called ADeS that may be able to detect and quantify apoptosis in live cell imaging⁸.

These novel techniques offer a broader range of tools to enhance the precision and efficiency of apoptosis analysis, which is vital for research in disease therapy.

Exploring new pathways in cancer therapeutics

Identifying new targets for apoptosis modulation in cancer treatment is pivotal in overcoming therapeutic resistance. Research focuses on activating or enhancing apoptosis pathways to selectively target cancer cells. Novel approaches include using agents that restore or activate p53 function, thereby reinstating tumor suppression^9,10.

For example, Gendicine (recombinant human p53 adenovirus) may be used to treat head and neck cancer. Transduced cells undergo apoptosis or autophagy when triggered by cell stress. This p53-based first-in-class gene therapy product has shown a good safety record and higher response with radio/chemotherapy over standard treatments. A phase II clinical trial (ClinicalTrials.gov identifier: NCT03931291) assessed the effect of eprenetapopt (small-molecule p53 reactivator) along with azacitidine as maintenance therapy in TP53-mutant (mTP53) acute myeloid leukemia and myelodysplastic syndromes after hematopoietic stem-cell transplant.

Drugs that stimulate the TRAIL and DR5 pathways target mutant p53 directly or inhibit anti-apoptotic proteins like B-2, Bcl-XL, and MCL-1 via BH3 mimetics, are advancing in trials, showing potential in treating apoptosis-resistant cancers¹¹. A few examples of such BH3 mimetics include A1210477, MIM1, S63845 and GDC-0941 (that target Mcl-1), Venetoclax (targets Bcl-2), ABT-737 (targets Bcl-2 and Bcl-xl).

Additionally, targeting IAPs with SMAC mimetics is currently being tested in clinical trials. For example, a phase II clinical trial (NCT02098161) tested the effect of monovalent SMAC mimetic LCL161 in patients with intermediate to high-risk myelofibrosis (after JAK inhibitor therapy. The trial showed a 30% objective response according to the Revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 2013 criteria¹².

Emerging approaches involve modulating mitochondrial pathways, autophagy-apoptosis crosstalk, and combining apoptosis-inducing therapies with immunotherapy or chemotherapy to overcome resistance. These advancements show promise in treating apoptosis-resistant cancers.

Trends in apoptosis and cell survival studies

The apoptotic pathway involving WISP1, PI3K, Akt, β-catenin, and mTOR regulates cell death and autophagy, offering potential therapeutic targets for diseases such as Alzheimer's, Parkinson's, and cancer. Pathways involving the IGFBP3/TMEM219 axis mediate cell death through caspase-8 activation, impacting disease processes by either promoting anti-proliferative effects or protecting specific tissues from damage, with potential therapeutic applications for conditions like diabetes and intestinal disorders.

Apoptotic inhibitors are emerging as targeted therapies for cancer by activating pathways that induce cell death in cancer cells, focusing on overcoming resistance mechanisms through proteins like TRAIL, DR agonists, and Bcl-2 inhibitors, and these have shown promising efficacy when combined with other targeted therapies^{13, 14}.

For instance, the DR5 agonist MEDI3039 could specifically target HER2+ and ER+ breast cancer cell lines and also improve animal survival in a lung cancer model. Further, the Bcl2 inhibitor, venetoclax, in combination with low dose cytarabine or the hypomethylating agents azacitidine and decitabine, was approved by the U.S. Food and Drug Administration for elderly acute myeloid leukemia who cannot receive chemotherapy¹⁵.

Alternative assays to detect markers of apoptosis

The key assays to detect the markers of apoptosis include:

• DNA fragmentation: is a key indicator of late apoptosis and can be studied using various methods. The TUNEL (Terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay detects DNA breaks by labeling free 3'-OH ends with fluorescent or chromogenic markers. The DNA ladder assay visualizes fragmented DNA on an agarose gel, where it appears as a characteristic “ladder” pattern. Flow cytometry is another valuable tool, quantifying apoptotic nuclei through propidium iodide staining following DNA fragmentation. Additional methods include the comet assay (single-cell gel electrophoresis), annexin V/PI double staining as a complementary approach, and immunohistochemistry techniques for identifying markers such as phosphorylated H2AX (γH2AX) and 53BP1 used to detect DNA damage¹⁶. These methods collectively provide comprehensive insights into DNA cleavage and apoptotic processes.
• Phosphatidylserine externalization: During early apoptosis, phosphatidylserine (PS) translocates from the inner to the outer leaflet of the plasma membrane. This process is commonly observed using the annexin V assay, where annexin V binds to PS. The assay is often combined with propidium iodide (PI) to distinguish between early apoptosis (Annexin V+/PI−) and late apoptosis or necrosis (Annexin V+/PI+). The results are typically analyzed through flow cytometry or fluorescence microscopy. Additional methods for studying PS translocation include immunofluorescence microscopy, protein biochemistry techniques of biochemical fractionation, mass spectrometry analysis and fluorescent PS-binding protein assays¹⁷.
• Mitochondrial membrane potential: The loss of mitochondrial membrane potential (MMP) is an early indicator of mitochondrial dysfunction during apoptosis. This can be detected using several methods. The JC-1 dye assay is a common technique where JC-1 accumulates in the mitochondria of healthy cells, forming red aggregates, while in apoptotic cells, it forms green monomers. Tetramethylrhodamine methyl ester (TMRM) and tetramethylrhodamine ethyl ester (TMRE) staining is also used to measure MMP through the use of tetramethylrhodamine dyes in fluorescence microscopy or flow cytometry. Flow cytometry is widely used to quantify changes in mitochondrial potential using fluorescent dyes, providing a robust method for analyzing MMP loss.
• Bcl-2 family proteins: Key markers of apoptosis include pro-apoptotic proteins, such as Bax, Bad, and Bak, and anti-apoptotic proteins, such as Bcl-2, Bcl-XL, and Bid-p15. These markers can be detected using several techniques. Western blotting is commonly used to quantify protein levels and detect cleavage events, such as Bax activation. Co-immunoprecipitation is employed to study interactions between pro- and anti-apoptotic proteins. Additionally, RT-qPCR is utilized to measure mRNA expression levels, providing insights into the transcriptional regulation of these proteins during apoptosis.
• Cytochrome C release: The release of Cytochrome C from mitochondria into the cytosol is a key marker of apoptosis, as it activates caspase-9. This can be detected using various methods. Western blotting is used to identify Cytochrome C in cytosolic and mitochondrial fractions. ELISA quantifies Cytochrome C levels in cytosolic extracts, while immunofluorescence microscopy provides a visual representation of Cytochrome C release. A Cytochrome C release assay kit offers a streamlined and reliable approach to detecting Cytochrome C translocation.
• Plasma membrane integrity: The loss of plasma membrane integrity occurs during late apoptosis or necrosis and is a marker of cell death. This can be assessed through several methods. Propidium iodide (PI) staining differentiates apoptotic cells (PI−) from necrotic or late apoptotic cells (PI+). The lactate dehydrogenase (LDH) assay measures LDH release as an indicator of membrane compromise. The trypan blue exclusion test is another method used to assess cell viability by staining non-viable cells.
• Apoptosis-related gene expression: Apoptosis-related gene expression is marked by the expression of genes such as those coding for p53 and Fas/FasL, which regulate the apoptotic process. Detection methods include RT-qPCR to quantify the expression of these genes, western blotting to detect apoptosis-related proteins like p53 and Fas/FasL, and chromatin immunoprecipitation (ChIP) to evaluate transcription factors binding to the promoters of apoptosis-related genes.

FAQs

What are the main advantages of using apoptosis antibodies in western blot techniques?

The main advantage of using apoptosis antibodies in western blot techniques is their ability to detect, localize, and quantify specific proteins involved in apoptotic signaling, providing precise insights into the stages and pathways of cell death in research contexts. The use of apoptosis antibodies in western blotting offers specificity in detecting apoptotic markers like caspases and Bcl-2 proteins, enabling differentiation between apoptosis and other cell death forms.

These antibodies detect cleaved proteins like caspase-3 and PARP, providing dynamic insights into apoptosis progression. Moreover, this technique allows simultaneous detection of multiple targets and applies across various biological models, making it invaluable for studying apoptosis in cancer, neurodegeneration, and immunology research.

What are the best markers for apoptosis?

Caspase activation can be detected by immunohistochemistry (IHC), flow cytometry, and western blot based on the sample type. Caspase 3 as an effector (executioner) has been detected in research for screening apoptosis. Based on the relative time, specific markers can be detected, although there would be overlaps in the markers, suggesting that multiple markers should be screened.

In terms of the relative time from live to dead cells, the markers include loss of membrane asymmetry (annexin V), Bcl-2 family protein cleavage (western blotting of the Bcl-2 family proteins), caspase activation (the active form of the caspase can be detected using microscopy/flow cytometry/spectrophotometry or by western blot of pro/active caspase), PARP cleavage (western blot or spectrophotometry), cathepsin activation (colorimetric/fluorometric assays), lowered mitochondrial transmembrane potential (δ ψm measurement), Cytochrome C release (using antibodies, increased G1 peak (flow cytometry), nuclear condensation (microscopy/flow cytometry), DNA fragmentation (agarose gel or TUNEL assay) and membrane blebbing (light microscopy or western blot of gelsolin, ROCK1).

References:

1. Barczyk, K., Kreuter, M., Pryjma, J., et al. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. International journal of cancer 116,167-173 (2005)
2. Leo, M., Amjad, A., Annika, P., et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 139, 1863-1877 (2022)
3. Labib, H.S., Salman, M.I., Halim, M.I., et al. Apoptosis in lupus nephritis patients: a study of Bcl-2 to assess glomerular and tubular damage. Egyptian rheumatology and rehabilitation 50, 20 (2023)
4. Tayeb, F. Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax. Exploration of medicine 5, 331-350 (2024)
5. Martinez, M.M., Reif, R.D, Pappas, D. Detection of apoptosis: a review of conventional and novel techniques. Analytical methods 2, 996 (2010)
6. Ping, L., Bowei, L., Longwen, F., et al. Hybrid three dimensionally printed paper-based microfluidic platform for investigating a cell’s apoptosis and intracellular cross-talk. ACS sensors 5, 464-473 (2020)
7. Lauwerys, L., Beroske, L., Solania, A., et al. Development of caspase-3-selective activity-based probes for PET imaging of apoptosis.  European journal of nuclear medicine and molecular imaging - Radiopharmacy and chemistry  9, 58 (2024)
8. Yuki, K., Yuki, O., Hiroaki, I., et al. AI-based apoptosis cell classification using phase-contrast images of K562 cells. Anticancer research 44, 935-939 (2024)
9. Zhang, W.W., Li, L., Li, D., et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Human gene therapy 29, 160-179 (2018)
10. Mishra, A., Tamari, R., DeZern, A.E., et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. Journal of clinical oncology 40, 3985-3993 (2022)
11. Townsend, P.A., Kozhevnikova, M.V., Cexus, O.N.F., et al. BH3-mimetics: recent developments in cancer therapy.  Journal of experimental and clinical cancer research  40, 355 (2021)
12. Pemmaraju, N., Carter, B.Z., Bose, P., et al. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood advances 5, 3163-3173 (2021)
13. Greer, Y.E., Gilbert, S.F., Gril, B., et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.  Breast cancer research  21, 27 (2019)
14. Carneiro, B.A., El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nature reviews clinical oncology 17, 395-417 (2020)
15. Richard-Carpentier, G., DiNardo, C.D. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Therapeutic advances in hematology 10 (2019)
16. Lee, Y., McKinnon, P.J. Detection of apoptosis in the central nervous system. Methods in molecular biology 559, 273-282 (2009)
17. Kay, J.G., Grinstein S. Sensing phosphatidylserine in cellular membranes. Sensors (Basel) 11, 1744-1755 (2011)